J
Julie M. Vose
Researcher at University of Nebraska Medical Center
Publications - 569
Citations - 51589
Julie M. Vose is an academic researcher from University of Nebraska Medical Center. The author has contributed to research in topics: Transplantation & Lymphoma. The author has an hindex of 97, co-authored 541 publications receiving 46915 citations. Previous affiliations of Julie M. Vose include Memorial Hospital of South Bend.
Papers
More filters
Journal ArticleDOI
Allogeneic transplantation for mantle cell lymphoma
Isabelle Bence-Bruckler,P. J. Bierman,Gregory Bociek,Douglas A. Stewart,Roger D. Gingrich,Julie M. Vose,Christopher Bredeson,M. Rosenblum,James C. Lynch,James O. Armitage +9 more
Journal ArticleDOI
Patients with Follicular Lymphoma, Grade 3, Have a Prolonged Relapse-Free Survival Following Aggressive Combination Chemotherapy.
Apar Kishor Ganti,Dennis D. Weisenburger,Lynette M. Smith,Christine P. Hans,R. Gregory Bociek,Philip J. Bierman,Julie M. Vose,James O. Armitage +7 more
TL;DR: In this paper, the authors conducted a retrospective study to identify the outcome and clinical features predictive of survival in patients with grade 3 follicular lymphoma (FL3) using the Berard criteria, who were staged and treated with various aggressive combination chemotherapy regimens containing either an anthracycline or mitoxantrone.
Journal ArticleDOI
Prognostic role of at-diagnosis positron emission tomography (PET) scan in follicular lymphoma grade 3 (FL3).
Vijaya Raj Bhatt,Julie M. Vose,Lynette M. Smith,Matthew A. Lunning,Martin Bast,Hina Naushad,Gregory Bociek,Philip J. Bierman,James O. Armitage +8 more
TL;DR: The survival tree method was utilized to determine an optimal cutoff of maximum standardized uptake value (SUVmax) in PET to predict overall survival (OS) and event-free survival (EFS) in FL3 patients.
Journal ArticleDOI
Anaplastic large cell lymphoma, alk-negative: analysis of 235 cases collected by the t-cell project
Andrei R. Shustov,Maria Elena Cabrera,Monica Bellei,Monica Civallero,Young-Hyeh Ko,Martina Manni,Steve Horwitz,C. Antonio De Souza,John Radford,Sabela Bobillo Varela,Maria Virginia Prates,Anna Ferreri,C.S. Chiattone,Michele Spina,Julie M. Vose,Annalisa Chiappella,Daniele Laszlo,Dario Marino,Caterina Stelitano,Tetiana Skrypets,Massimo Federico +20 more
TL;DR: Research Funding: Agensys, Bristol Myers Squibb, Celgene, Forty Seven, Inc., Genentech/Roche, Infinity, Janssen Pharmaceutical, Kura, Merck, Millennium, Pharmacyclics, Regeneron, Seattle Genetics.
Journal ArticleDOI
HIV-Associated Plasmablastic Lymphoma: A Multi-Institutional Study
Michael Furman,Pascual Balsalobre,Brady E Beltran,Michele Bibas,Mark Bower,Weina Chen,Silvia Montoto,Roberto N. Miranda,Nahid M. Nanaji,José-Tomás Navarro,Adam C. Seegmiller,Julie M. Vose,Jorge J. Castillo +12 more
TL;DR: PBL is a rare aggressive B-cell lymphoma, which tends to affect young HIV-positive men who have CD4+ counts 90% at presentation, and adverse prognostic factors for survival included non-CR to chemotherapy, female sex and advanced stage are common features of HIV PBL.